Pharma Whistleblowers Need Solid Proof, Appeals Court Rules

Washington Drug Letter
A federal appeals court has raised the bar for whistleblowers filing False Claims Act (FCA) suits against drugmakers, saying they must provide specific information about the fraudulent claims made, not just broad allegations about a drugmaker’s conduct.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00